Actinogen is an Australian Stock Exchange listed company developing UE2343 for Alzheimer’s disease.
Aquila BioMedical provides specialist in vitro and in vivo drug profiling services to the pharma/biotech industries. It is increasingly focused on the provision of in vitro models for the assessment of immune-modulating drugs and biologics.
Edinburgh Molecular Imaging
EM Imaging is developing a range of diagnostic ‘probes’ for the rapid detection of respiratory disease and colorectal cancer.
NeurocentRx Pharma Ltd
NeurocentRx is a specialty pharma company focusing on cancer-related pain and the palliative/supportive care market.
Triscribe is a start-up company developing potential hospital prescription analysis products for the pharmaceutical industry and other customers.